Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Cassava Sciences Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.48 (market cap $3.62B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: iShares MSCI United Kingdom (FTSE) is far larger — about 91.9× Cassava Sciences Inc's market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Cassava Sciences Inc for 37 Days on average.
| EWU | FLNA | |
|---|---|---|
Market Cap | $3.62B | $39.40M |
Volume | 923,896 | 759,018 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $4.64 |
52-Week Low | $41.34 | $0.68 |
Typical Hold Time | 46 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.445, up 1.12% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is trading near key support levels at $46, with RSI indicators showing mixed signals. Recent UK market volatility driven by rising gilt yields and inflation concerns creates headwinds for this UK-focused ETF.
The outlook remains cautious given the bearish technical momentum and macroeconomic pressures from rising UK borrowing costs. Investment opportunity exists for contrarian investors if support holds, but risks include further interest rate hikes and economic uncertainty in the UK market.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
